Fox Run Management L.L.C. Acquires New Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Fox Run Management L.L.C. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,676 shares of the biopharmaceutical company’s stock, valued at approximately $524,000.

A number of other large investors have also recently modified their holdings of GILD. FMR LLC raised its position in Gilead Sciences by 79.4% in the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after purchasing an additional 14,680,161 shares during the last quarter. Wellington Management Group LLP boosted its position in Gilead Sciences by 50.9% during the 3rd quarter. Wellington Management Group LLP now owns 34,600,676 shares of the biopharmaceutical company’s stock worth $2,900,921,000 after buying an additional 11,665,593 shares during the period. Pacer Advisors Inc. grew its holdings in Gilead Sciences by 723.3% during the 4th quarter. Pacer Advisors Inc. now owns 6,434,665 shares of the biopharmaceutical company’s stock worth $594,370,000 after acquiring an additional 5,653,075 shares during the last quarter. Raymond James Financial Inc. acquired a new position in Gilead Sciences in the 4th quarter valued at approximately $207,340,000. Finally, Point72 Asset Management L.P. grew its stake in shares of Gilead Sciences by 350.1% in the third quarter. Point72 Asset Management L.P. now owns 2,305,270 shares of the biopharmaceutical company’s stock worth $193,274,000 after purchasing an additional 1,793,145 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.1 %

NASDAQ:GILD opened at $107.89 on Wednesday. The firm has a market capitalization of $134.36 billion, a P/E ratio of 291.59, a PEG ratio of 0.71 and a beta of 0.21. The company’s fifty day moving average price is $104.35 and its 200-day moving average price is $94.36. Gilead Sciences, Inc. has a 1-year low of $62.07 and a 1-year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s dividend payout ratio (DPR) is presently 854.05%.

Insiders Place Their Bets

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total value of $228,375.00. Following the sale, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold a total of 302,785 shares of company stock valued at $30,503,250 in the last 90 days. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

GILD has been the subject of several analyst reports. DZ Bank upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 price target for the company in a report on Thursday, February 13th. BMO Capital Markets boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a report on Wednesday, February 12th. Royal Bank of Canada increased their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Finally, Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and raised their target price for the stock from $80.00 to $120.00 in a research note on Tuesday, February 18th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $104.52.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.